BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8632299)

  • 1. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
    von Moltke LL; Greenblatt DJ; Harmatz JS; Duan SX; Harrel LM; Cotreau-Bibbo MM; Pritchard GA; Wright CE; Shader RI
    J Pharmacol Exp Ther; 1996 Feb; 276(2):370-9. PubMed ID: 8632299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences.
    Greenblatt DJ; Wright CE; von Moltke LL; Harmatz JS; Ehrenberg BL; Harrel LM; Corbett K; Counihan M; Tobias S; Shader RI
    Clin Pharmacol Ther; 1998 Sep; 64(3):237-47. PubMed ID: 9757147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms.
    Perloff MD; von Moltke LL; Court MH; Kotegawa T; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):618-28. PubMed ID: 10640299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ketoconazole on triazolam pharmacokinetics, pharmacodynamics and benzodiazepine receptor binding in mice.
    Fahey JM; Pritchard GA; Moltke LL; Pratt JS; Grassi JM; Shader RI; Greenblatt DJ
    J Pharmacol Exp Ther; 1998 Apr; 285(1):271-6. PubMed ID: 9536021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Counihan M; Graf JA; Durol AL; Mertzanis P; Duan SX; Wright CE; Shader RI
    Clin Pharmacol Ther; 1998 Sep; 64(3):278-85. PubMed ID: 9757151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of age on in vitro midazolam biotransformation in male CD-1 mouse liver microsomes.
    Warrington JS; Poku JW; von Moltke LL; Shader RI; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1024-31. PubMed ID: 10688619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Mertzanis P; Graf JA; Durol AL; Counihan M; Roth-Schechter B; Shader RI
    Clin Pharmacol Ther; 1998 Dec; 64(6):661-71. PubMed ID: 9871431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat.
    Kotegawa T; Laurijssens BE; Von Moltke LL; Cotreau MM; Perloff MD; Venkatakrishnan K; Warrington JS; Granda BW; Harmatz JS; Greenblatt DJ
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1228-37. PubMed ID: 12183684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
    von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Wright CE; Shader RI
    J Clin Psychopharmacol; 1996 Apr; 16(2):104-12. PubMed ID: 8690825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general.
    Boxenbaum H
    J Pharm Pharm Sci; 1999; 2(2):47-52. PubMed ID: 10952769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo.
    von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Duan SX; Harmatz JS; Shader RI
    J Pharmacol Exp Ther; 1994 Mar; 268(3):1278-83. PubMed ID: 8138941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
    Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
    Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.
    von Moltke LL; Greenblatt DJ; Cotreau-Bibbo MM; Harmatz JS; Shader RI
    Br J Clin Pharmacol; 1994 Jul; 38(1):23-31. PubMed ID: 7946933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alprazolam-ritonavir interaction: implications for product labeling.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
    Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
    von Moltke LL; Greenblatt DJ; Schmider J; Duan SX; Wright CE; Harmatz JS; Shader RI
    J Clin Pharmacol; 1996 Sep; 36(9):783-91. PubMed ID: 8889898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of age on in vitro triazolam biotransformation in male human liver microsomes.
    Patki KC; von Moltke LL; Harmatz JS; Hesse LM; Court MH; Greenblatt DJ
    J Pharmacol Exp Ther; 2004 Mar; 308(3):874-9. PubMed ID: 14634046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions.
    von Moltke LL; Greenblatt DJ; Granda BW; Grassi JM; Schmider J; Harmatz JS; Shader RI
    Psychopharmacology (Berl); 1999 Jul; 145(1):113-22. PubMed ID: 10445380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.
    von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Shader RI
    J Clin Pharmacol; 1994 Dec; 34(12):1222-7. PubMed ID: 7738219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    J Pharmacol Exp Ther; 2001 Apr; 297(1):326-37. PubMed ID: 11259560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.